vectors with enhanced photoreceptor targeting for retinal gene therapy. Localization and distribution of Müller glia cells (CRALBP, red) in retinal organoids. Nuclear DAPI staining (blue).

Researchers at Massachusetts Eye and Ear developed a preclinical research proof of concept that shows mRNA-based therapies ...

The global macular degeneration treatment market is poised for significant growth, projected to expand from USD 9.1 billion ...

Francesca Simonelli Session title: Multicentric longitudinal study in Usher Syndrome IB: disease course and implication for gene therapy Session: Inherited retinal diseases treatments About the ...

It is focusing on retinal diseases, with its most advanced ... to legal blindness when they reach their early forties. The gene therapy was acquired from US biotech AGTC in 2022 by Syncona ...

It is the first pivotal trial of a mutation-agnostic RP gene therapy and the only study to show a 0.3 or better LogMAR improvement in retinal degenerative disease, according to Nanoscope.

Harvard Medical School researchers have taken another decisive step in their efforts to develop a gene therapy for people ...

Researchers have developed a dual-gene therapy approach to treat Usher syndrome type 1F, a rare condition causing deafness and progressive blindness.

The United States Food and Drug Administration has just approved the first-ever clinical trial that uses CRISPR-Cas13 RNA ...

This research evaluates the effects of various gene therapy viral vectors on RPE cells to determine efficacy for therapeutic ...

A team of UC Davis Health researchers has shown that CD34+ stem cells can be safely administered into retinitis pigmentosa ...